Moleculin Biotech (MBRX) Earnings Date & Reports

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

MBRX is expected to report earnings to fall 109.42% to -64 cents per share on November 09

Moleculin Biotech MBRX Stock Earnings Reports

Q3'26

Est.

$-0.65

Q4'25

Beat

by $8.15

Q3'25

Beat

by $0.57

Q2'25

Beat

by $0.76

Q4'23

Missed

by $1.79

The last earnings report on March 18 showed earnings per share of $6.90, beating the estimate of -125 cents. With 1.37M shares outstanding, the current market capitalization sits at 14.15M.

View a ticker or compare two or three

MBRX

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for MBRX